Over the past three years, Philip Morris International (PMI) has made a dramatic pivot away from the marketing and sales of combustible cigarettes, and moved towards its Reduced-Risk Product (RRP) portfolio, focusing on its flagship product, IQOS. This launch of this product is PMI’s step forward to creating a smoke-free future for legal age consumers who continue to enjoy tobacco, but are seeking smoke-free alternatives. All of this has been accompanied by an organization-wide transformation in ways of working, culture, and strategy, with emphasis on digital, consumer and collaborator strategies.
Do you look for ways to learn and grow in an international environment? Do you want to build a remarkable career? Are you up for a 6-month challenge starting as of July 2019? Then apply now! We are looking for you!
Intern Organotypic Studies
You have the following skills/experience:
• Currently studying for your Master degree in Life Sciences, biology or related area
• Strong background in biology and some experience in mammalian cell culture technique.
• You are interested in learning new cell culture and molecular biology techniques, with a special focus in 3D organotypic tissues.
• You are fluent in English.
If you are also good at leading a wide variety of studies and taking ownership, you enjoy learning while operating in a changing international environment, you are excellent in delivering results in a timely manner, and you have an effective and impactful communication style, you are the person we want for our internship within our Systems Toxicology department at Philip Morris Products SA, based in Neuchâtel, Switzerland.
You will be working on 2 specific projects related to the development of three dimensional cellular models and to the evaluation of different protocols to best maintain these models. This is your opportunity to work with cutting-edge technologies in a state-of-art research environment.
Philip Morris International: Building a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free IQOS product portfolio includes heated tobacco and nicotine-containing vapor products. As of Dec. 31, 2018, PMI estimates that approximately 6.6 million adult smokers around the world have already stopped smoking and switched to PMI’s heated tobacco product, which is currently available for sale in 44 markets in key cities or nationwide under the IQOS brand. For more information, see our PMI and PMIScience websites.
PMI is an Equal Opportunity Employer.
A valid Swiss work permit or Swiss or EU-25/EFTA citizenship is required for this position.